Skip to main content

The D.K. Hoffman COVID Research & Recovery Virtual Laboratory

FREE · NO ACCOUNT

A free, live workbench for COVID-19 & Long COVID research and recovery — the latest studies, recruiting trials, vaccine & safety data, treatment options, interactive recovery simulators, and a private symptom journal. A HYVE CARES research lab.

The D.K. Hoffman Laboratory is a research and education tool, not medical advice. It surfaces published science and registered trials so you can explore the evidence and bring it to a qualified clinician. Nothing here is a diagnosis, treatment recommendation, or substitute for professional care. In an emergency, call your local emergency number.

What causes Long COVID?

Leading hypotheses for what drives Long COVID — likely several act together.

Viral persistencegrowing evidence

Fragments or reservoirs of SARS-CoV-2 (viral RNA / spike protein) may linger in tissues such as the gut for months, keeping the immune system activated. This is a leading driver and the rationale behind antiviral trials for Long COVID.

Immune dysregulation & autoimmunitygrowing evidence

Long COVID is associated with lasting immune changes — exhausted/activated T cells, altered cytokines, and autoantibodies that attack the body's own tissues. This overlaps with how some autoimmune diseases behave.

Microclots & endothelial dysfunctioncontested evidence

Some researchers report tiny fibrin-rich 'microclots' resistant to normal breakdown, plus damage to blood-vessel linings, which could impair oxygen delivery to tissues. Promising but still contested — assays and clinical relevance are debated.

Autonomic dysfunction (dysautonomia / POTS)established evidence

Dysregulation of the autonomic nervous system — which controls heart rate, blood pressure and digestion — is commonly observed, frequently presenting as POTS (a large heart-rate jump on standing). This is one of the most clinically recognizable Long COVID patterns.

Latent virus reactivation (EBV / HHV-6)emerging evidence

SARS-CoV-2 infection may reawaken dormant herpesviruses such as Epstein–Barr virus (EBV), which has independently been linked to chronic fatigue. Reactivation has been proposed as a contributor in a subset of patients.

Gut microbiome & serotonin depletionemerging evidence

Disruption of gut bacteria and reduced serotonin signaling (with viral RNA persisting in the gut) have been proposed to affect the gut–brain axis, potentially contributing to fatigue and cognitive symptoms.

Mitochondrial & metabolic dysfunctionemerging evidence

Impaired cellular energy production (mitochondrial dysfunction) and altered metabolism are studied as a basis for post-exertional malaise — the hallmark crash after activity shared with ME/CFS.

Symptom clusters

Symptoms tend to group into recognizable clusters.

Fatigue & post-exertional malaise (PEM)
Profound fatigueCrash after activity (PEM)Unrefreshing sleepWeakness

The most common and disabling cluster; PEM overlaps strongly with ME/CFS and shapes 'pacing' strategies.

Cognitive ('brain fog')
Memory problemsTrouble concentratingSlowed processingWord-finding difficulty

Objective deficits in attention and processing speed have been measured in studies.

Cardiovascular & autonomic
PalpitationsRacing heart on standing (POTS)Chest painDizziness

Frequently reflects dysautonomia; POTS is a recognizable, testable pattern.

Respiratory
BreathlessnessCoughReduced exercise tolerance

Can persist even when lung imaging looks normal.

Neurological & sensory
HeadacheLoss/change of smell or tasteTingling/numbnessSleep disturbanceTinnitus

Smell/taste changes (parosmia) are a hallmark of COVID specifically.

Gastrointestinal
NauseaAbdominal painAltered bowel habitsAppetite loss

Aligns with the gut-reservoir / microbiome hypotheses.

Treatments being studied

Under investigation — NOT endorsements. Tap to find live trials.

Nirmatrelvir/ritonavir (Paxlovid)
Targets: Viral persistence · Tested in RECOVER & other trials
Metformin
Targets: Antiviral / metabolic · Reduced Long COVID risk in a prevention trial; under study
Low-dose naltrexone (LDN)
Targets: Neuroinflammation / immune · Early-phase trials
Pacing & PEM management
Targets: Post-exertional malaise · Standard supportive approach (ME/CFS-derived)
Beta-blockers / ivabradine
Targets: POTS / autonomic · Symptomatic management; under study
Immunomodulators / IVIG
Targets: Autoimmunity · Investigational; select cases
Antiplatelet / anticoagulation
Targets: Microclots / coagulation · Investigational; caution (bleeding risk)
Data: Europe PMC + PubMed (NCBI), ClinicalTrials.gov, openFDA — all public, free, and queried live. The D.K. Hoffman Laboratory surfaces published science so you can bring it to a qualified clinician. It is not medical advice.